Provided by Tiger Fintech (Singapore) Pte. Ltd.

Vertex, Inc.

35.45
+0.51001.46%
Post-market: 35.450.00000.00%17:50 EDT
Volume:725.56K
Turnover:25.60M
Market Cap:5.62B
PE:-125.04
High:35.52
Open:35.44
Low:34.77
Close:34.94
Loading ...

Why Vertex Pharmaceuticals Stock Is a Screaming Buy on the Dip

Motley Fool
·
07 May

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Vertex Pharmaceuticals (VRTX), Waters (WAT) and ZimVie Inc (ZIMV)

TIPRANKS
·
07 May

Barclays Reaffirms Their Hold Rating on Vertex Pharmaceuticals (VRTX)

TIPRANKS
·
07 May

Vertex Appoints Joint CFO

MT Newswires Live
·
07 May

Vertex Pharmaceuticals’ Earnings Call Highlights Growth and Challenges

TIPRANKS
·
07 May

Vertex downgraded to Peer Perform from Outperform at Wolfe Research

TIPRANKS
·
07 May

Vertex Pharmaceuticals price target raised to $621 from $617 at Goldman Sachs

TIPRANKS
·
07 May

Vertex Pharmaceuticals Stock Is Tumbling After Earnings. Here's Why. -- Barrons.com

Dow Jones
·
07 May

Why Vertex Pharmaceuticals Stock Is Sinking Today

Motley Fool
·
06 May

Vertex Pharmaceuticals Is Maintained at Overweight by JP Morgan

Dow Jones
·
06 May

Goldman Sachs Adjusts Price Target on Vertex Pharmaceuticals to $621 From $617

MT Newswires Live
·
06 May

Vertex Pharmaceuticals Price Target Maintained With a $535.00/Share by Cantor Fitzgerald

Dow Jones
·
06 May

Vertex Pharmaceuticals Cut to Market Perform From Outperform by Leerink Partners

Dow Jones
·
06 May

Leerink Partners Downgrades Vertex Pharmaceuticals to Market Perform From Outperform, Adjusts Price Target to $503 From $550

MT Newswires Live
·
06 May

Vertex Pharmaceuticals: Hold Rating Amid Revenue Misses and Strategic Outlook

TIPRANKS
·
06 May

Vertex Pharmaceuticals downgraded to Market Perform from Outperform at Leerink

TIPRANKS
·
06 May

Vertex Pharmaceuticals: Strong Market Performance and Promising Future Prospects Reinforce Buy Rating

TIPRANKS
·
06 May

Vertex Pharmaceuticals Inc (VRTX) Q1 2025 Earnings Call Highlights: Revenue Growth Amid Challenges

GuruFocus
·
06 May

Vertex Pharmaceuticals (VRTX) Misses Q1 Earnings and Revenue Estimates

Zacks
·
06 May

Vertex Pharmaceuticals Stock Falls On Q1 Earnings, Revenue Miss — Company Raises Low End Of FY25 Revenue Guidance

Benzinga
·
06 May